Answers are grounded in this paper and cite their sources.
As newer neural-network methods are applied to survival analysis, it is important to determine whether they improve prediction in relatively small clinical datasets. Our study compared model discrimination between conventional Cox regression and a DeepSurv neural network implemented in PyTorch to predict survival in historical TCGA glioblastoma patients with reported IDH-wildtype status. Both models used expression of the same four genes: OSMR, HOXC10, SCARA3, and SLC39A10. The primary measure of model performance was the C-index, with time-dependent AUC and Brier prediction error at one year as secondary measures. Age and sex were added in exploratory analyses to assess changes in performance. DeepSurv did not outperform conventional Cox regression in the main 139-patient four-gene analysis, returning a C-index of 0.567 compared with 0.591 for the refitted Cox model. The fixed published score developed by Cao et al. using the same genes returned a C-index of 0.614. Because the Cao score was developed using overlapping TCGA data, it served as a contextual benchmark rather than an independent validation. Adding age and sex yielded small numerical increases in the main-cohort C-index (DeepSurv, 0.577; Cox, 0.597). These findings show no observed advantage from the tested neural network over Cox regression in this internal comparison. Potential explanations that are not explored in this study but can be theorized are data missingness, overfitting, and limited data set size. The small historical cohort and lack of independent validation limit broader conclusions or clinical use at this time.
No takes yet. Share an insight, caveat, or question.
Soloniuk et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: